vs
CRH PUBLIC LTD CO（CRH）与Stryker Corporation（SYK）财务数据对比。点击上方公司名可切换其他公司
CRH PUBLIC LTD CO的季度营收约是Stryker Corporation的1.3倍（$9.4B vs $7.2B），Stryker Corporation净利率更高（11.8% vs 10.9%，领先1.0%），Stryker Corporation同比增速更快（11.4% vs 6.2%），过去两年CRH PUBLIC LTD CO的营收复合增速更高（20.1% vs 16.9%）
CRH是总部位于爱尔兰都柏林的知名建材供应商，主要生产骨料、水泥等建筑材料，同时制造预拌混凝土、沥青混凝土及基建部件，是北美地区规模最大的建材供应商之一，目前在北美、欧洲、澳大利亚、菲律宾等28个国家设有3816个运营网点。
斯特赖克是一款八轮装甲战车，衍生自加拿大LAV III步兵战车，而后者源自瑞士莫瓦格食人鱼系列装甲车。该型战车由加拿大通用动力陆地系统公司为美国陆军生产，制造工厂位于安大略省伦敦市。它默认采用8×4四轮驱动，可切换为8×8全轮驱动模式。
CRH vs SYK — 直观对比
营收规模更大
CRH
是对方的1.3倍
$7.2B
营收增速更快
SYK
高出5.3%
6.2%
净利率更高
SYK
高出1.0%
10.9%
两年增速更快
CRH
近两年复合增速
16.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.4B | $7.2B |
| 净利润 | $1.0B | $849.0M |
| 毛利率 | 35.6% | 64.5% |
| 营业利润率 | 14.9% | 25.2% |
| 净利率 | 10.9% | 11.8% |
| 营收同比 | 6.2% | 11.4% |
| 净利润同比 | 45.8% | 55.5% |
| 每股收益（稀释后） | $1.51 | $2.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRHSYK
| Q4 25 | $9.4B | $7.2B | ||
| Q3 25 | $11.1B | $6.1B | ||
| Q2 25 | $10.2B | $6.0B | ||
| Q1 25 | $6.8B | $5.9B | ||
| Q4 24 | $8.9B | $6.4B | ||
| Q3 24 | $10.5B | $5.5B | ||
| Q2 24 | $9.7B | $5.4B | ||
| Q1 24 | $6.5B | $5.2B |
净利润CRHSYK
| Q4 25 | $1.0B | $849.0M | ||
| Q3 25 | $1.5B | $859.0M | ||
| Q2 25 | $1.3B | $884.0M | ||
| Q1 25 | $-94.0M | $654.0M | ||
| Q4 24 | $703.0M | $546.0M | ||
| Q3 24 | $1.4B | $834.0M | ||
| Q2 24 | $1.3B | $825.0M | ||
| Q1 24 | $116.0M | $788.0M |
毛利率CRHSYK
| Q4 25 | 35.6% | 64.5% | ||
| Q3 25 | 38.9% | 63.6% | ||
| Q2 25 | 39.4% | 63.8% | ||
| Q1 25 | 27.2% | 63.8% | ||
| Q4 24 | 35.6% | 64.9% | ||
| Q3 24 | 38.6% | 64.0% | ||
| Q2 24 | 38.1% | 63.0% | ||
| Q1 24 | 27.7% | 63.6% |
营业利润率CRHSYK
| Q4 25 | 14.9% | 25.2% | ||
| Q3 25 | 18.8% | 18.7% | ||
| Q2 25 | 19.0% | 18.5% | ||
| Q1 25 | 0.3% | 14.3% | ||
| Q4 24 | 12.4% | 9.0% | ||
| Q3 24 | 18.7% | 19.7% | ||
| Q2 24 | 18.9% | 19.4% | ||
| Q1 24 | 0.4% | 18.5% |
净利率CRHSYK
| Q4 25 | 10.9% | 11.8% | ||
| Q3 25 | 13.6% | 14.2% | ||
| Q2 25 | 12.9% | 14.7% | ||
| Q1 25 | -1.4% | 11.1% | ||
| Q4 24 | 7.9% | 8.5% | ||
| Q3 24 | 13.1% | 15.2% | ||
| Q2 24 | 13.4% | 15.2% | ||
| Q1 24 | 1.8% | 15.0% |
每股收益（稀释后）CRHSYK
| Q4 25 | $1.51 | $2.20 | ||
| Q3 25 | $2.21 | $2.22 | ||
| Q2 25 | $1.94 | $2.29 | ||
| Q1 25 | $-0.15 | $1.69 | ||
| Q4 24 | $1.01 | $1.41 | ||
| Q3 24 | $1.97 | $2.16 | ||
| Q2 24 | $1.88 | $2.14 | ||
| Q1 24 | $0.16 | $2.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.1B | $4.0B |
| 总债务越低越好 | $17.5B | — |
| 股东权益账面价值 | $24.0B | $22.4B |
| 总资产 | $58.3B | $47.8B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
现金及短期投资CRHSYK
| Q4 25 | $4.1B | $4.0B | ||
| Q3 25 | $4.2B | $3.3B | ||
| Q2 25 | $2.9B | $2.4B | ||
| Q1 25 | $3.4B | $2.3B | ||
| Q4 24 | $3.7B | $3.7B | ||
| Q3 24 | $3.0B | $3.9B | ||
| Q2 24 | $3.1B | $1.9B | ||
| Q1 24 | $3.3B | $2.3B |
总债务CRHSYK
| Q4 25 | $17.5B | — | ||
| Q3 25 | $18.6B | — | ||
| Q2 25 | $15.7B | — | ||
| Q1 25 | $15.6B | — | ||
| Q4 24 | $13.9B | — | ||
| Q3 24 | $13.7B | — | ||
| Q2 24 | $13.0B | — | ||
| Q1 24 | $12.6B | — |
股东权益CRHSYK
| Q4 25 | $24.0B | $22.4B | ||
| Q3 25 | $23.3B | $21.8B | ||
| Q2 25 | $22.3B | $21.2B | ||
| Q1 25 | $21.1B | $20.9B | ||
| Q4 24 | $21.6B | $20.6B | ||
| Q3 24 | $21.9B | $20.1B | ||
| Q2 24 | $20.7B | $19.8B | ||
| Q1 24 | $20.0B | $19.2B |
总资产CRHSYK
| Q4 25 | $58.3B | $47.8B | ||
| Q3 25 | $58.5B | $47.1B | ||
| Q2 25 | $54.0B | $46.3B | ||
| Q1 25 | $51.9B | $46.0B | ||
| Q4 24 | $50.6B | $43.0B | ||
| Q3 24 | $51.2B | $43.8B | ||
| Q2 24 | $48.1B | $39.1B | ||
| Q1 24 | $46.3B | $39.4B |
负债/权益比CRHSYK
| Q4 25 | 0.73× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | 0.63× | — | ||
| Q1 24 | 0.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.9B | $2.1B |
| 自由现金流经营现金流 - 资本支出 | — | $1.9B |
| 自由现金流率自由现金流/营收 | — | 26.1% |
| 资本支出强度资本支出/营收 | — | 3.7% |
| 现金转化率经营现金流/净利润 | 2.84× | 2.52× |
| 过去12个月自由现金流最近4个季度 | — | $4.3B |
8季度趋势，按日历期对齐
经营现金流CRHSYK
| Q4 25 | $2.9B | $2.1B | ||
| Q3 25 | $2.0B | $1.5B | ||
| Q2 25 | $1.4B | $1.1B | ||
| Q1 25 | $-659.0M | $250.0M | ||
| Q4 24 | $2.7B | $1.9B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $633.0M | ||
| Q1 24 | $-712.0M | $204.0M |
自由现金流CRHSYK
| Q4 25 | — | $1.9B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $723.0M | $928.0M | ||
| Q1 25 | $-1.3B | $127.0M | ||
| Q4 24 | $1.8B | $1.7B | ||
| Q3 24 | $981.0M | $1.3B | ||
| Q2 24 | $861.0M | $481.0M | ||
| Q1 24 | $-1.2B | $37.0M |
自由现金流率CRHSYK
| Q4 25 | — | 26.1% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | 7.1% | 15.4% | ||
| Q1 25 | -19.3% | 2.2% | ||
| Q4 24 | 20.1% | 25.9% | ||
| Q3 24 | 9.3% | 23.7% | ||
| Q2 24 | 8.9% | 8.9% | ||
| Q1 24 | -18.6% | 0.7% |
资本支出强度CRHSYK
| Q4 25 | — | 3.7% | ||
| Q3 25 | — | 3.1% | ||
| Q2 25 | 6.4% | 3.0% | ||
| Q1 25 | 9.5% | 2.1% | ||
| Q4 24 | 10.6% | 4.1% | ||
| Q3 24 | 4.8% | 3.1% | ||
| Q2 24 | 6.5% | 2.8% | ||
| Q1 24 | 7.7% | 3.2% |
现金转化率CRHSYK
| Q4 25 | 2.84× | 2.52× | ||
| Q3 25 | 1.32× | 1.79× | ||
| Q2 25 | 1.04× | 1.26× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | 3.88× | 3.54× | ||
| Q3 24 | 1.08× | 1.77× | ||
| Q2 24 | 1.14× | 0.77× | ||
| Q1 24 | -6.14× | 0.26× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRH
| Products | $7.1B | 76% |
| Essential Materials | $1.4B | 15% |
| Outdoor Living Solutions | $842.0M | 9% |
SYK
| Medical | $1.3B | 18% |
| Endoscopy | $1.1B | 16% |
| Traumaand Extremities | $1.1B | 15% |
| Instruments | $925.0M | 13% |
| Knees | $749.0M | 10% |
| Neuro Cranial | $669.0M | 9% |
| Neurovascular | $539.0M | 8% |
| Hips | $499.0M | 7% |
| Other Orthopaedics | $267.0M | 4% |
| Spine | $8.0M | 0% |
